title: Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.
abstract: We previously produced a recombinant version of the human anti-RhD antibody Fog-1 in the rat myeloma cell line, YB2/0. When human, autologous RhD-positive red blood cells (RBC) were sensitised with this IgG1 antibody and re-injected, they were cleared much more rapidly from the circulation than had been seen earlier with the original human-mouse heterohybridoma-produced Fog-1. Since the IgG have the same amino acid sequence, this disparity is likely to be due to alternative glycosylation that results from the rat and mouse cell lines. By comparing the in vitro properties of YB2/0-produced Fog-1 IgG1 and the same antibody produced in the mouse myeloma cell line NS0, we now have a unique opportunity to pinpoint the cause of the difference in ability to clear RBC in vivo. Using transfected cell lines that express single human FcγR, we showed that IgG1 made in YB2/0 and NS0 cell lines bound equally well to receptors of the FcγRI and FcγRII classes but that the YB2/0 antibody was superior in FcγRIII binding. When measuring complexed IgG binding, the difference was 45-fold for FcγRIIIa 158F, 20-fold for FcγRIIIa 158V and approximately 40-fold for FcγRIIIb. The dissimilarity was greater at 100-fold in monomeric IgG binding assays with FcγRIIIa. When used to sensitise RBC, the YB2/0 IgG1 generated 100-fold greater human NK cell antibody-dependent cell-mediated cytotoxicity and had a 103-fold advantage over the NS0 antibody in activating NK cells, as detected by CD54 levels. In assays of monocyte activation and macrophage adherence/phagocytosis, where FcγRI plays major roles, RBC sensitised with the two antibodies produced much more similar results. Thus, the alternative glycosylation profiles of the Fog-1 antibodies affect only FcγRIII binding and FcγRIII-mediated functions. Relating this to the in vivo studies confirms the importance of FcγRIII in RBC clearance.
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Armour
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Cheryl S
authors.initials: CS
authors.lastname: Smith
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Natasha C Y
authors.initials: NC
authors.lastname: Ip
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Cara J
authors.initials: CJ
authors.lastname: Ellison
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Kirton
authors.affiliation: Bristol Institute for Transfusion Sciences, Bristol, United Kingdom.
authors.forename: Anthony M
authors.initials: AM
authors.lastname: Wilkes
authors.affiliation: National Health Service Blood and Transplant, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Lorna M
authors.initials: LM
authors.lastname: Williamson
authors.affiliation: Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Clark
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D002460:Cell Line; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D051379:Mice; D051381:Rats; D017452:Receptors, IgG / Q000378:metabolism*
chemical_list: D000906:Antibodies; D007074:Immunoglobulin G; D017452:Receptors, IgG